Theophylline Treatment for Pseudohypoparathyroidism – Children 2-12 Years Old

Pseudohypoparathyroidism

Disorders of Bone and Mineral Metabolism QoL and Cognitive Function in Patients With Hypoparathyroidism Theophylline Treatment for Pseudohypoparathyroidism – Children 2-12 Years Old Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments Hypoparathyroidism in Denmark Physiologic Regulation of FGF-23 Theophylline Treatment for Pseudohypoparathyroidism Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a Glucose Homeostasis in Pseudohypoparathyroidism Theophylline for Treatment of Pseudohypoparathyroidism Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)